Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published January 1, 2022 | Supplemental Material + Published
Journal Article Open

Speech-generated aerosol settling times and viral viability can improve COVID-19 transmission prediction

Abstract

Droplets during human speech are found to remain suspended in the air for minutes, while studies suggest that the SARS-CoV-2 virus is infectious in experimentally produced aerosols for more than one hour. However, the absence of a large-scale association between regional outbreaks and weather-influenced virus-laden speech-generated aerosol characteristics such as settling time and viral viability makes it challenging for policy making on appropriate infection control measures. Here we investigate the correlation between the time series of daily infections and of settling times of virus-containing particles produced by speaking. Characteristic droplet settling times determined by the Stokes–Cunningham equation as influenced by daily weather conditions were estimated based on local meteorological data. Daily infection data were calibrated from local reported cases based on established infection timeframes. Linear regression, vector autoregression, simple recurrent neural network, and long short-term memory models predict transmission rates within one-sigma intervals using the settling times and viral viability over 5 days before the day of prediction. Corroborating with previous health science studies, from the perspective of meteorology-modulated transmission, our results strengthen that airborne aerosol transmission is an important pathway for the spread of SARS-CoV-2. Furthermore, historical weather data can improve the prediction accuracy of infection spreading rates.

Additional Information

© 2021 The Author(s). Published by the Royal Society of Chemistry. This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. Submitted 19 Feb 2021. Accepted 25 Nov 2021. First published 08 Dec 2021. This work is supported by the Bill & Melinda Gates Foundation Investment Grant INV-018569. The authors thank Paul Dabisch at National Biodefense Analysis and Countermeasures Center for sharing his insights on SARS-CoV-2 viability. The authors would like to acknowledge Richard Flagan for helpful discussions.

Attached Files

Published - d1ea00013f.pdf

Supplemental Material - d1ea00013f1.pdf__ga=2.177883685.1627782830.1639070284-494341399.1632163545

Files

d1ea00013f.pdf
Files (1.1 MB)
Name Size Download all
md5:ef78d853d301f8e814c4cbcd0dbb23d9
1.1 MB Preview Download

Additional details

Created:
August 20, 2023
Modified:
October 23, 2023